iOmx Therapeutics AG, a biopharmaceutical company at the forefront of developing cutting-edge cancer immunotherapy treatments, today announced a major milestone with the dosing of the first patient in a Phase I clinical trial of their revolutionary OMX-0407 oral SIK inhibitor. This is the first-of-its-kind therapy, aimed at treating cancer in a more targeted and effective manner.
OMX-0407, a novel monotherapy, is being evaluated in a groundbreaking single-arm, open-label, multicenter, Phase I clinical trial for the treatment of previously treated unresectable solid tumors. The clinical trial has been given the green light by regulators in Spain and Belgium, and is set to provide insight into the safety and tolerability of OMX-0407 as a potential treatment option.
The potential of OMX-0407 to address multiple solid tumors unresponsive to conventional treatments is truly exciting. Our research has revealed that OMX-0407 has the power to potentiate tumor cell apoptosis by unleashing intra-tumoral death receptor signaling, leading to anti-tumor efficacy in pre-clinical models that were previously resistant to other treatments.
We are deeply grateful to the investigators, their teams, and the patient community for their unwavering support and trust in our treatment approach with OMX-0407.
Dr. Apollon Papadimitriou, CEO of iOmx, expressed his pride at the launch of the company’s first iOTarg platform-derived product candidate in the clinic. This milestone is a major step forward in iOmx’s mission to provide more effective treatments for cancer patients whose current immunotherapies are not working.
Using iOmx’s revolutionary iOTargTM platform, SIK3, a member of the SIK family, was identified as a novel immune-protective kinase with the potential to provide a groundbreaking treatment for cancer.
Upon inhibition of SIK3 with OMX-0407, preclinical studies have demonstrated strong monotherapy effects, successfully reshaping the immune compartment and driving tumor cell death. This cutting-edge approach targets a novel immune evasion biology, sensitizing tumors to immune-derived ligands of the TNF superfamily.
OMX-0407 is an exciting breakthrough in cancer treatment as it has the potential to treat tumors that evade death receptor-mediated killing. This oral salt-inducible kinase (SIK) inhibitor works by downregulating the NF-κB driven gene landscape and phosphorylation of class IIa histone deacetylases (HDACs) and CREB-regulated transcriptional coactivators.
In preclinical studies, this has been shown to potentiate apoptosis by death receptor ligands, such as tumor necrosis factor (TNF) and TNF-related apoptosis-inducing ligand (TRAIL). With this innovative therapy, we may be able to combat even the most aggressive forms of cancer.
About the study
The first-in-human, dose-escalation trial of OMX-0407 monotherapy is an exciting opportunity for patients with previously treated unresectable solid tumors. The Phase I trial aims to evaluate the safety, tolerability, and pharmacodynamic activity of OMX-0407. Through a 3+3 design, the trial seeks to establish the maximum tolerated dose (MTD). Join us in this groundbreaking endeavor to explore the potential of OMX-0407!
About iOmx Therapeutics
iOmx Therapeutics is on a mission to develop first-in-class cancer immuno-therapeutics that address novel immune checkpoints hijacked by cancer cells. Through its iOTarg™ high-throughput screening platform, the company has identified a number of proprietary tumor-associated next-generation immune checkpoints and is advancing a preclinical stage pipeline of drug candidates that could potentially address cancers resistant to current immunotherapies.
Founded in 2016 by Dr. Philipp Beckhove and Dr. Nisit Khandelwal of the German Cancer Research Center, iOmx is supported by international venture capital investors such as Wellington Partners, Sofinnova Partners, MIG Capital and Athos Biopharma. Located in Martinsried/Munich, Germany, the company’s lead compound OMX-0407 is an innovative solution that targets SIK, an immune protective kinase family in multiple solid tumors.